Literature DB >> 23522325

Outcome of salvage surgery for anal squamous cell carcinoma.

D A Harris1, J Williamson, M Davies, M D Evans, P Drew, J Beynon.   

Abstract

AIM: The purpose of this study was to examine factors related to treatment failure following chemoradiotherapy for squamous cancer and to compare the outcome of salvage surgery in one unit with national audit standards published by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) (ACPGBI position statement for management of anal cancer. Colorectal Disease 2011; 13(Suppl. 1): 1-52).
METHOD: Patients with squamous cell carcinoma of the anus treated with radical intent between 1997 and 2010 in a single tertiary referral oncology institute were prospectively identified. Multivariate analysis was used to establish factors associated with treatment failure. Cancer-specific end-points after salvage surgery were determined by Kaplan-Meier survival analysis.
RESULTS: Ninety-five patients received chemoradiotherapy with radical intent with a 5-year overall survival of 83% (all stages) at a median follow up of 35 months. Of these, 11 (12%) required salvage surgery, five of whom were Stage T4 at presentation. Six patients had failed to respond to chemoradiotherapy and five presented with recurrence at a median of 10 (10-36) months. Only Stage T4 disease at presentation was predictive of the need for salvage surgery (OR 5.6, CI 4.9-6.3, P = 0.015). There was no surgical mortality and no delayed perineal healing where a myocutaneous flap was used. The resection margin was involved in one (9%) patient. The 5-year survival rate was 64%. Audit standards for case selection, local control, survival and perineal complications were achieved.
CONCLUSION: Long-term survival was achieved in two- thirds of patients following salvage surgery after failed primary chemoradiotherapy for anal cancer in a multidisciplinary oncological unit. Stage T4 disease at presentation strongly predicted the need for subsequent salvage intervention. Colorectal Disease
© 2013 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Anal cancer; audit; outcome; reconstruction; surgery

Mesh:

Year:  2013        PMID: 23522325     DOI: 10.1111/codi.12222

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  7 in total

1.  Abdominoperineal resection and perineal wound healing in recurrent, persistent, or primary anal carcinoma.

Authors:  J Hardt; S Mai; C Weiß; Peter Kienle; J Magdeburg
Journal:  Int J Colorectal Dis       Date:  2016-03-31       Impact factor: 2.571

2.  [Primary treatment of anal cancer].

Authors:  H Dralle; K Kols; H Witzigmann; R Viebahn
Journal:  Chirurg       Date:  2018-02       Impact factor: 0.955

3.  Long-term results achieved by guideline-based stage-dependent management of anal cancer in a non-HIV population.

Authors:  Bernhard Fankhaenel; Joerg Zimmer; Dorothea Bleyl; Eric Puffer; Andreas Schreiber; Thomas Kittner; Helmut Witzigmann; Sigmar Stelzner
Journal:  Int J Colorectal Dis       Date:  2019-10-22       Impact factor: 2.571

Review 4.  The differential diagnosis and interdisciplinary treatment of anal carcinoma.

Authors:  Dimitrios Raptis; Ignaz Schneider; Klaus E Matzel; Oliver Ott; Rainer Fietkau; Werner Hohenberger
Journal:  Dtsch Arztebl Int       Date:  2015-04-03       Impact factor: 5.594

5.  Salvage abdominoperineal excisions in recurrent anal cancer--impact of different reconstruction techniques on outcome, morbidity, and complication rates.

Authors:  Sabine Hannes; Alexander Reinisch; Wolf O Bechstein; Nils Habbe
Journal:  Int J Colorectal Dis       Date:  2015-12-21       Impact factor: 2.571

Review 6.  Background and Current Treatment of Squamous Cell Carcinoma of the Anus.

Authors:  Rob Glynne-Jones; Waqar Saleem; Mark Harrison; Suzy Mawdsley; Marcia Hall
Journal:  Oncol Ther       Date:  2016-08-01

7.  Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).

Authors:  R Fish; C Sanders; N Ryan; S Van der Veer; A G Renehan; P R Williamson
Journal:  Colorectal Dis       Date:  2018-04-17       Impact factor: 3.788

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.